| Project/Area Number |
15H06073
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | macrocyclic peptides / in vitro selection / RaPID system / receptors / signaling / TGFbeta / cancer / cancer signaling |
|---|
| Outline of Final Research Achievements |
TGF-beta signaling is implicated in cancer progression. The goal of this project is to regulate TGF-beta signaling by preventing signal transduction into the cell. We aim to identify a macrocyclic peptide or macrocyclic peptides that bind to the type 1 receptor ALK1 and prevent its interaction with the cytokine BMP and/or the type 2 receptor, thereby blocking signal transduction. After in vitro selection, a promising macrocyclic peptide, ALK1-3R6-5, was identified from a diverse library of over 10^12 unique macrocyclic peptides. Chemical synthesis of ALK1-3R6-5 derivatives is underway.
|
